Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...
Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a press release from the manufacturer ...
Atopic dermatitis (AD) is typically a big issue during early childhood. But it also afflicts up to 5% of adults. Mild cases, which are virtually always managed in primary care, are usually ...
Please provide your email address to receive an email when new articles are posted on . 50% of patients treated with dupilumab achieved complete remission of blistering lesions. Sixteen patients ...
Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including ...
A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
In this exclusive MedPage Today video, Thomas B. Casale, MD, of the University of South Florida in Tampa, discusses new analyses from the LIBERTY-CUPID studies evaluating dupilumab (Dupixent) in ...
TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Hives, or what doctors call urticaria, are red, itchy, and sometimes painful welts that show up on your skin. If you have chronic spontaneous urticaria (CSU), your hives occur spontaneously and recur ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results